Switch theme
Sign up to access all valuation multiples
Hofseth BioCare ASA is a Norway-based company engaged in the business of developing, manufacturing, marketing, and selling marine ingredients such as oil, calcium, and protein products. Its products and their respective brands include salmon oil (OmeGo), hydrolyzed soluble protein (ProGo), Calcium/Collagen (CalGo or NT-II), and non-soluble protein (PetGo), all of which are produced in the Midsund plant. The firm sells its products to various segments of the human nutrition market, such as sports nutrition, supplements, and health foods, as well as to the market within nutrition for the pet and feed industry. It generates maximum revenue from the sale of salmon oil. Geographically, the company generates maximum revenue from Europe, followed by North America and Asia.
2009
78
Last FY Revenue $25.2M
Last FY EBITDA -$6.8M
$101M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, Hofseth BioCare achieved revenue of $25.2M and an EBITDA of -$6.8M.
Hofseth BioCare expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Hofseth BioCare valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | $25.2M | XXX | XXX | XXX |
| Gross Profit | XXX | $8.6M | XXX | XXX | XXX |
| Gross Margin | XXX | 34% | XXX | XXX | XXX |
| EBITDA | XXX | -$6.8M | XXX | XXX | XXX |
| EBITDA Margin | XXX | -27% | XXX | XXX | XXX |
| EBIT | XXX | -$11.1M | XXX | XXX | XXX |
| EBIT Margin | XXX | -44% | XXX | XXX | XXX |
| Net Profit | XXX | -$12.2M | XXX | XXX | XXX |
| Net Margin | XXX | -49% | XXX | XXX | XXX |
| Net Debt | XXX | $4.9M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Hofseth BioCare's stock price is NOK 2 (or $0).
Hofseth BioCare has current market cap of NOK 869M (or $85.0M), and EV of NOK 1.0B (or $101M).
See Hofseth BioCare trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $101M | $85.0M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Hofseth BioCare has market cap of $85.0M and EV of $101M.
Hofseth BioCare's trades at 4.0x EV/Revenue multiple, and -14.8x EV/EBITDA.
Equity research analysts estimate Hofseth BioCare's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Hofseth BioCare's P/E ratio is not available.
See valuation multiples for Hofseth BioCare and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $85.0M | XXX | $85.0M | XXX | XXX | XXX |
| EV (current) | $101M | XXX | $101M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 4.0x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -14.8x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | -9.1x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | -6.9x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -74.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialHofseth BioCare's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.3M for the same period.
Hofseth BioCare's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Hofseth BioCare's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Hofseth BioCare and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -27% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 6% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 4% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 78% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| SynBiotic | XXX | XXX | XXX | XXX | XXX | XXX |
| Mega Lifesciences | XXX | XXX | XXX | XXX | XXX | XXX |
| Procter & Gamble Health | XXX | XXX | XXX | XXX | XXX | XXX |
| Abbott India | XXX | XXX | XXX | XXX | XXX | XXX |
| Sanofi India | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Hofseth BioCare acquired XXX companies to date.
Last acquisition by Hofseth BioCare was XXXXXXXX, XXXXX XXXXX XXXXXX . Hofseth BioCare acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Hofseth BioCare founded? | Hofseth BioCare was founded in 2009. |
| Where is Hofseth BioCare headquartered? | Hofseth BioCare is headquartered in Norway. |
| How many employees does Hofseth BioCare have? | As of today, Hofseth BioCare has 78 employees. |
| Who is the CEO of Hofseth BioCare? | Hofseth BioCare's CEO is Mr. Jon Olav Odegard. |
| Is Hofseth BioCare publicy listed? | Yes, Hofseth BioCare is a public company listed on OSL. |
| What is the stock symbol of Hofseth BioCare? | Hofseth BioCare trades under HBC ticker. |
| When did Hofseth BioCare go public? | Hofseth BioCare went public in 2011. |
| Who are competitors of Hofseth BioCare? | Similar companies to Hofseth BioCare include e.g. SynBiotic, Mega Lifesciences, Procter & Gamble Health, Abbott India. |
| What is the current market cap of Hofseth BioCare? | Hofseth BioCare's current market cap is $85.0M |
| Is Hofseth BioCare profitable? | Yes, Hofseth BioCare is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
